TMO
Thermo Fisher Scientific Inc. · Healthcare · Medical - Diagnostics & Research
Momentum inputs (comparable managers):
holder breadth -3.3% ·
share flow +4.2% ·
net new positions -6.9%
— formula
Concentrated accumulation — rising shares among fewer holders
All ownership figures: tracked 13F managers only, common-stock positions, reporting period Q3 2025
| Quarter | Holders | Δ | Shares | Reported value | New | Exits |
|---|---|---|---|---|---|---|
| Q2 2026 | 191 | +3 | 260.72M | $131.51B | +5 | −1 |
| Q1 2026 | 190 | +2 | 255.88M | $126.62B | +7 | −6 |
| Q4 2025 | 187 | +3 | 274.75M | $159.19B | +4 | — |
| Q3 2025 | 29 | -1 | 154.46M | $74.90B | +1 | −3 |
| Q2 2025 | 28 | +3 | 123.95M | $50.25B | +3 | — |
| Q1 2025 | 22 | -2 | 60.64M | $30.17B | — | −2 |
| Q4 2024 | 24 | +2 | 61.50M | $31.99B | +2 | — |
| Q3 2024 | 21 | -2 | 44.46M | $27.48B | — | −2 |
| Q2 2024 | 23 | — | 44.78M | $24.75B | — | — |
| # | Manager | Shares | Δ shares | Value | Their weight | Held | ||
|---|---|---|---|---|---|---|---|---|
| 1 | The Vanguard Group ✦ (passive) | 33.85M | +0.2% | $16.42B | 0.2% | ▲ Add | 2 | SEC ↗ ×6 |
| 2 | BlackRock ✦ (passive) | 29.64M | +8.4% | $14.37B | 0.3% | ▲ Add | 2 | SEC ↗ ×21 |
| 3 | State Street Global Advisors ✦ (passive) | 16.38M | -0.6% | $7.95B | 0.3% | ▼ Trim | 4 | SEC ↗ |
| 4 | JPMorgan Chase ✦ | 14.55M | — | $7.06B | 0.2% | n/c | 1 | SEC ↗ ×40 |
| 5 | Morgan Stanley ✦ | 12.72M | — | $6.17B | 0.4% | n/c | 1 | SEC ↗ ×24 |
| 6 | Capital World Investors ✦ | 10.29M | +7.4% | $4.99B | 0.7% | ▲ Add | 6 | SEC ↗ |
| 7 | Geode Capital Management ✦ (passive) | 8.17M | +0.7% | $3.94B | 0.3% | ▲ Add | 6 | SEC ↗ ×2 |
| 8 | Fidelity (FMR) ✦ | 7.59M | +90.3% | $3.68B | 0.2% | ▲ Add | 2 | SEC ↗ ×7 |
| 9 | T. Rowe Price ✦ | 6.47M | +16.4% | $3.14B | 0.3% | ▲ Add | 6 | SEC ↗ ×2 |
| 10 | Fisher Asset Management ✦ | 2.72M | +1.2% | $1.32B | 0.5% | ▲ Add | 6 | SEC ↗ |
| 11 | Wellington Management ✦ | 2.70M | +88.9% | $1.31B | 0.2% | ▲ Add | 6 | SEC ↗ ×9 |
| 12 | Goldman Sachs Group ✦ | 2.60M | — | $1.26B | 0.2% | n/c | 1 | SEC ↗ ×6 |
| 13 | PRIMECAP Management ✦ | 2.30M | -4.3% | $1.12B | 0.9% | ▼ Trim | 6 | SEC ↗ |
| 14 | Arrowstreet Capital ✦ | 1.27M | +4.6% | $614.10M | 0.4% | ▲ Add | 6 | SEC ↗ |
| 15 | Adage Capital Partners ✦ | 538.88K | +65.4% | $261.37M | 0.4% | ▲ Add | 6 | SEC ↗ |
| 16 | Marshall Wace ✦ | 505.46K | +36.0% | $245.16M | 0.3% | ▲ Add | 2 | SEC ↗ ×2 |
| 17 | Millennium Management ✦ | 497.09K | +59.8% | $241.10M | 0.2% | ▲ Add | 6 | SEC ↗ |
| 18 | Baillie Gifford ✦ | 491.23K | -2.7% | $238.26M | 0.2% | ▼ Trim | 6 | SEC ↗ ×4 |
| 19 | Citadel Advisors ✦ | 349.70K | -68.1% | $169.61M | 0.1% | ▼ Trim | 6 | SEC ↗ ×2 |
| 20 | Glenview Capital ✦ | 282.94K | +182.9% | $137.23M | 3.3% | ▲ Add | 2 | SEC ↗ |
| 21 | Point72 Asset Management ✦ | 169.45K | -54.4% | $82.19M | 0.2% | ▼ Trim | 4 | SEC ↗ |
| 22 | AQR Capital Management ✦ | 155.61K | +43.2% | $72.43M | 0.0% | ▲ Add | 6 | SEC ↗ ×6 |
| 23 | Gotham Asset Management ✦ | 71.78K | -10.0% | $34.81M | 0.2% | ▼ Trim | 6 | SEC ↗ |
| 24 | D. E. Shaw & Co. ✦ | 64.46K | -95.1% | $31.26M | 0.0% | ▼ Trim | 6 | SEC ↗ ×2 |
| 25 | Markel Group ✦ | 55.80K | +12.6% | $27.06M | 0.2% | ▲ Add | 6 | SEC ↗ |
| 26 | Dodge & Cox ✦ | 25.74K | -0.8% | $12.48M | 0.0% | ▼ Trim | 6 | SEC ↗ |
| 27 | Two Sigma Investments ✦ | 9.53K | -98.5% | $4.62M | 0.0% | ▼ Trim | 6 | SEC ↗ |
| 28 | GAMCO Investors ✦ | 5.14K | -2.8% | $2.49M | 0.0% | ▼ Trim | 6 | SEC ↗ |
| 29 | Harris Associates (Oakmark) ✦ | 541 | New | $262,396 | 0.0% | New | 1 | SEC ↗ |
“Their weight” = the position's share of that manager's reported 13F equity value — the conviction measure. ✦ = curated manager.
New buyers
| Harris Associates (Oakmark) | $262,396 | 0.0% |
Exited
| Norges Bank | $2.26B | was 0.3% |
| Renaissance Technologies | $186.09M | was 0.2% |
| Duquesne Family Office | $4.95M | was 0.1% |
Full-market context: across ALL 13F filers (SEC structured data, Q1 2026): 1 holders, 24.30K shares, $11,944 reported. This is a different, older period than the tracked-universe figures above and the two are never mixed.
What else this security's tracked holders most often hold — shared-ownership counts, not fundamental relationships.
Open-market purchases (P)
No open-market insider purchases in our coverage window.
Open-market sales (S)
Officer · 3.73K sh · $2.29M
Officer · 400 sh · $245,752
Officer, Director · 62 sh · $38,982
Officer, Director · 33 sh · $20,677
Officer, Director · 101 sh · $63,166
Officer, Director · 79 sh · $49,613
Officer, Director · 2.15K sh · $1.35M
Officer, Director · 1.79K sh · $1.12M
Officer, Director · 3.01K sh · $1.89M
Officer, Director · 2.73K sh · $1.71M
Awards, exercises and tax withholding are never counted as buys or sales here. Methodology